Working with leading health care organizations to solve for adoption gap in AI. It has been easier to build AI solutions but understanding the performance and having safety guardrails is the real challenge. The generative AI solutions have huge potential but are stuck because of lack of trust and safety.

The Avasant Distinguished Fellows are a world-class team of experts and leaders, comprised of the top minds within the technology world. The group includes former and current CXOs, CIOs, and other senior technology executives who bring business value to Avasant and its clients. The Fellows are an independent, yet integral part of Avasant’s management consulting and IT advisory services.

Provide independent, unbiased advice to innovative health care companies at all stages. Representative projects include:• Circle Cardiovascular Imaging – Marketing strategy post acquisition by ThomaBravo• Labcorp - Crafted unified marketing collateral tailored to support C-suite sales• PE Firm - Contributed to PE diligence efforts in the acquisition of large consulting firms healthcare division and post acquisition management support of back-office IT and product post acquisition • Series A Startup - Supported commercial re-launch of revenue cycle AI company • Seed Stage - Created GTM strategy and product concept for AI/NLP technology team

External partnerships – Managed for-profit subsidiary growing seed capital from $2M to $4M over 4 years from $2M license to national revenue cycle firm and multiple 10-15% revenue share co-development deals.‒ Benefits maximation – risk free contract and equity – $3M equity and $2M in guaranteed savings ‒ Automated documentation software – vendor cost reduction and direct revenue – $3M over four years ‒ Video education platform – vendor cost reduction and direct revenue – $4M over six years ‒ Executive HSM program – negotiated seed funding to launch program – $1M over three yearsSystemization efforts reporting to System CEO/COO/CFO, examples:‒ Negotiated revenue cycle co-sourcing deal – Annual cash yield improvement by ~$30M over 3 years‒ Reference lab and clinical trial partnership – Improved expenses by $500k annually and growth of trials ‒ Developed systemization and long-term financial plan for three system labs with $60M operating budget and major capital needs - Proforma reduced CapEx and improved Opex.‒ Led work to consolidate three multi-specialty groups ($600M operating budget, 1000 providers), including potential sale of unprofitable specialties.‒ Supported transformation of inpatient care models to reduce labor cost and improve quality.

• Served in an interim management role of RUSH IT Organization during global pandemic, including 400 FTEs, six data centers, $100M operating budget and $50M capital budget• Reduced operational expense by $7M within first year to support organizational financial goals.• Conducted end-to-end benchmarking effort and identified 20% overall cost reduction opportunity via rationalization of technical debt and modernization of applications and infrastructure.• Secured funding for modernization effort within a challenging financial climate.

Innovation and Technology Transfer - Restructured academic office leading to $2M annual operating income improvement from 2019 – 2022 via a combination of cost rationalization and revenue optimization.

The Advisory Board Company was acquired by United Health Group in November 2017

- Led build of a unified data management platform enabling cost-effective scale and strategic agility by ingesting all health system data into a data lake; applying common transformations, bindings, and business logic; and efficiently making curated data domains available to Advisory Board’s full suite of technology products and general purpose analytics platform- Altering business processes and tools to enable larger body of Advisory Board subject matter experts to directly author client deliverables on platform, reducing cost and time to value by up to 90%- Representing Advisory Board on Argonaut and SMART on FHIR governing boards and leading internal initiatives to drive standards-based integration with client source systems- Developing go to market strategy for Advisory Board Enterprise Analytics offering and integration with Optum Analytics The Advisory Board Company was acquired by United Health Group in November 2017

- Managed $80M portfolio of SaaS-based analytic and workflow applications that support health system growth via physician referral and consumer oriented analytics- Increased analytics application development velocity by 90% by implementing standards and template driven designs- Created terrain-level strategy to guide development of previously stand-alone products and redefined go-to-market approach - Supported client sales and renewal efforts and led client specific portfolio strategy

- Envisioned and delivered analytics value proposition to existing publication and meeting business - Built analytics and software team and launched over 200 discrete analytic apps during tenure- Drove YoY increase in utilization achieving over 50% penetration into CXO user base - Maintained near flat cost via rigorous road map management and technological innovation including the adoption of big data technologies- Led research and analytics team that developed operational and financial opportunity assessments, case studies, and training materials to standardize value delivery during a period of rapid growth

- Supported initial launch, product scope, and management of over 40 client projects as founding member of Service Line Strategy Advisor team. - Launched Medical Technology Solutions custom research business and personally managed seven client relationships from initial sales, project scoping, pricing, project execution, and delivery

- Identified >$300MM in annual cost savings for a major telecommunications firm’s access network - Identified a $225MM annual revenue opportunity for a super regional bank developing a new service platform and supported development of business plan to help capture the opportunity within 4 years- Delineated technical requirements for a global paper manufacturer entering the $1.4B pharmaceutical packaging market - Performed diligence for private equity client considering purchase of target companies in various industries, such as cement manufacturing and electric utility